Lv43
410 积分 2023-04-18 加入
Novel potent and highly selective DDR1 inhibitors from integrated lead finding
48分钟前
已完结
Automated Molecular Design in BRADSHAW, Applied to the Optimization of ERAP1 Inhibitors
4小时前
已完结
Unlocking the Therapeutic Potential of the Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitors in Alzheimer’s Diseases
21小时前
已完结
Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy
1天前
已完结
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies
5天前
已完结
NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
5天前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
5天前
已完结
Discovery of Naphthyridinone Derivatives as Selective PKMYT1/WEE1 Dual Inhibitors for Cancer Therapy
6天前
已完结
Ketone reduction drives major circulating metabolites of GDC-8264 in humans
8天前
已关闭
Evaluation of Oral PROTAC Guidelines: Efflux Ratio Outweighs Chameleonicity Descriptors
9天前
已完结
皖公网安备34019202002308